… , most cancer cells largely depend on the cystine transporter system x c − to import cystine, …
We will focus on SLC7A11 and refer to this cystine transporter as SLC7A11 throughout this …

… transporter for cystine and glutamate, and its role in various diseases, particularly cancer. …
as sulfasalazine may prove useful in clinical cancer therapy, particularly in combination with …

… transporter, which is electrically neutral and non-Na + dependent. Under physiological
conditions, extracellular cystine is … , is synthesized by rapidly reducing cystine into cysteine (Cys) …

… of breast cancer cells, and determines breast cancer cell response to antioxidant N-acetylcysteine.
Thus, SLC3A1 can serve as a potential target for breast cancer therapy. …

… ), a potent inhibitor of the xc À cystine transporter. … therapy of a variety of cancers [2,3]. It is
based on inhibition of uptake of extracellular cystine (or the reduced form, cysteine) by cancers …

… or alkylating drugs used in cancer therapy, affording an important … transporter (RBAT,
also designated by SLC3A1) is another cystine transporter with possible implications in cancer …

… therapy using glucose transporter (GLUT) inhibitors can trigger disulfidptosis and inhibit
cancer … and high expression in kidney cancer cells mediates high rates of cystine uptake. The …

… cells can provide insights for targeting metabolic vulnerabilities in cancer therapies. One
notable example is the use of asparaginase to treat acute lymphoblastic leukaemia. Unlike …

… Cells can acquire either cysteine or cystine (Cys-SS-Cys) for incorporation into GSH. The …
cystine to cysteine. Accordingly, one of the targets of sulfasalazine is the cystine transporter xCT…

… Tumor cells rely mainly on the nutrient transporter protein SLC7A11 to obtain cystine from
extrinsic pathway and then reduce it to cysteine by consuming reduced nicotinamide adenine …